-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Pharmaceutical Stock Market] On July 28, Penghua's TCM ETF, which closely tracks the CSI TCM Index, will be officially listed for tradi.
The CSI Traditional Chinese Medicine Index mainly selects securities of listed companies involved in the production and sales of traditional Chinese medicines as samples to reflect the overall performance of listed companies with the concept of traditional Chinese medicine, and to provide investors with a convenient tool to invest in the field of traditional Chinese medici.
According to Wind data, as of July 26, 2022, the CSI Traditional Chinese Medicine Index has a total of 50 constituent stocks, with a total market value of over 900 billion yu.
Since the base date (December 31, 2004), the index has risen by 9591%, far exceeding the gains of the CSI 300 and CSI 500 indices in the same peri.
Among them, in 2019, 2020, and 2021, the annual growth rate of the CSI Traditional Chinese Medicine Index was 03%, 145%, and 357%, respective.
As of June 30, 2022, the annualized rate of return in the past three years was 111%, significantly outperforming the same peri.
Market performan.
The top ten stocks in the CSI Traditional Chinese Medicine Index are Pien Tze Huang, Yunnan Baiyao, Tong Ren Tang, Baiyun Mountain, Yiling Pharmaceutical, China Resources Sanjiu, Guangyuyuan, Dong E E Jiao, Hongri Pharmaceutical, Jilin Aodong, and ten shares are heavily weight.
It accounts for more than 55% of the total weight of the index, and the excess returns are considerab.
In addition, as of June 30, 2022, the CSI Traditional Chinese Medicine Index PE was valued at 353 tim.
Traditional Chinese medicine is a national treasure and an important resour.
With the intensification of population aging, consumption upgrades, the improvement of residents' recognition of traditional Chinese medicine, and the expansion of medical consumption demand, the traditional Chinese medicine industry is expected to maintain a good growth tre.
According to Frost & Sullivan data, the TCM health industry chain is expected to reach 2,973 billion yuan in 203
In addition, in recent years, the relevant favorable policies from the state to the local government have also supported the development of traditional Chinese medicine, and the previous overall planning outline has been converted into more specific development rules, including medical insurance payment, drug review and approval, talent training, e.
In terms of support, the standardized development of sub-tracks such as research and development of traditional Chinese medicine, formula granules, and traditional Chinese medicine diagnosis and treatment is support.
For example, in 2022, the "14th Five-Year Plan for the Development of Traditional Chinese Medicine" was issued, which made specific recommendations in the aspects of TCM supply and total resources, construction of quality standards, access to medical insurance, TCM innovation, and TCM internationalizati.
Development requirements; the policy on cultivating traditional Chinese medicine talents jointly issued by the four ministries and commissions points out a more specific direction for the cultivation of traditional Chinese medicine talen.
These policies will help improve the fundamentals of the Chinese medicine industry and reshape its valuation, and the mid- and long-term allocation value of the Chinese medicine industry can be expect.
In the long run, many securities companies are optimistic about the long-term development of traditional Chinese medici.
For example, Haitong Securities stated that the "14th Five-Year Plan for the Development of Traditional Chinese Medicine" in 2022 has formulated comprehensive and clear strategic goals and mission requirements for the development of the traditional Chinese medicine industry from the perspectives of supply, demand and management, and solved the problem of Chinese medici.
The main pain points and bottlenecks in the current development of the pharmaceutical indust.
The signal of the state's policy support for the Chinese medicine industry is obvious, and the payment side, the hospital side and the pharmaceutical side have all benefit.
The industry has a large room for expansion, and I am optimistic about the long-term development of the Chinese medicine indust.
Minsheng Securities also released a research report saying that traditional Chinese medicine OTC itself has no risk of centralized procurement, and the out-of-hospital market has independent pricing power, which helps products maintain a high profit marg.
Maintain a steady growth trend for a long ti.
The agency focuses on two directions, one is the targets with exclusive varieties and confidential varieties, with high intellectual property barriers, and the other is the targets with omni-channel coverage and brand strength, with significant brand effects and rapid product volu.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
The CSI Traditional Chinese Medicine Index mainly selects securities of listed companies involved in the production and sales of traditional Chinese medicines as samples to reflect the overall performance of listed companies with the concept of traditional Chinese medicine, and to provide investors with a convenient tool to invest in the field of traditional Chinese medici.
According to Wind data, as of July 26, 2022, the CSI Traditional Chinese Medicine Index has a total of 50 constituent stocks, with a total market value of over 900 billion yu.
Since the base date (December 31, 2004), the index has risen by 9591%, far exceeding the gains of the CSI 300 and CSI 500 indices in the same peri.
Among them, in 2019, 2020, and 2021, the annual growth rate of the CSI Traditional Chinese Medicine Index was 03%, 145%, and 357%, respective.
As of June 30, 2022, the annualized rate of return in the past three years was 111%, significantly outperforming the same peri.
Market performan.
The top ten stocks in the CSI Traditional Chinese Medicine Index are Pien Tze Huang, Yunnan Baiyao, Tong Ren Tang, Baiyun Mountain, Yiling Pharmaceutical, China Resources Sanjiu, Guangyuyuan, Dong E E Jiao, Hongri Pharmaceutical, Jilin Aodong, and ten shares are heavily weight.
It accounts for more than 55% of the total weight of the index, and the excess returns are considerab.
In addition, as of June 30, 2022, the CSI Traditional Chinese Medicine Index PE was valued at 353 tim.
Traditional Chinese medicine is a national treasure and an important resour.
With the intensification of population aging, consumption upgrades, the improvement of residents' recognition of traditional Chinese medicine, and the expansion of medical consumption demand, the traditional Chinese medicine industry is expected to maintain a good growth tre.
According to Frost & Sullivan data, the TCM health industry chain is expected to reach 2,973 billion yuan in 203
In addition, in recent years, the relevant favorable policies from the state to the local government have also supported the development of traditional Chinese medicine, and the previous overall planning outline has been converted into more specific development rules, including medical insurance payment, drug review and approval, talent training, e.
In terms of support, the standardized development of sub-tracks such as research and development of traditional Chinese medicine, formula granules, and traditional Chinese medicine diagnosis and treatment is support.
For example, in 2022, the "14th Five-Year Plan for the Development of Traditional Chinese Medicine" was issued, which made specific recommendations in the aspects of TCM supply and total resources, construction of quality standards, access to medical insurance, TCM innovation, and TCM internationalizati.
Development requirements; the policy on cultivating traditional Chinese medicine talents jointly issued by the four ministries and commissions points out a more specific direction for the cultivation of traditional Chinese medicine talen.
These policies will help improve the fundamentals of the Chinese medicine industry and reshape its valuation, and the mid- and long-term allocation value of the Chinese medicine industry can be expect.
In the long run, many securities companies are optimistic about the long-term development of traditional Chinese medici.
For example, Haitong Securities stated that the "14th Five-Year Plan for the Development of Traditional Chinese Medicine" in 2022 has formulated comprehensive and clear strategic goals and mission requirements for the development of the traditional Chinese medicine industry from the perspectives of supply, demand and management, and solved the problem of Chinese medici.
The main pain points and bottlenecks in the current development of the pharmaceutical indust.
The signal of the state's policy support for the Chinese medicine industry is obvious, and the payment side, the hospital side and the pharmaceutical side have all benefit.
The industry has a large room for expansion, and I am optimistic about the long-term development of the Chinese medicine indust.
Minsheng Securities also released a research report saying that traditional Chinese medicine OTC itself has no risk of centralized procurement, and the out-of-hospital market has independent pricing power, which helps products maintain a high profit marg.
Maintain a steady growth trend for a long ti.
The agency focuses on two directions, one is the targets with exclusive varieties and confidential varieties, with high intellectual property barriers, and the other is the targets with omni-channel coverage and brand strength, with significant brand effects and rapid product volu.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
